LIVIVO - Search results -

Search results

Result 1 - 10 of total 254

Search options

Article: Meta-Analysis of Demographic Disparities in Monkeypox Infections among Diverse Populations.

Kandeel, Mahmoud

2024 Volume 46, Issue 4, Page(s) 322–331

Abstract: This meta-analysis aims to investigate demographic disparities in monkeypox (mpox) infections among various groups based on ethnicity, sexual partners, and gender. The study includes data from 2,646 to 4,002 patients across various outcomes. Among racial ...

Abstract	This meta-analysis aims to investigate demographic disparities in monkeypox (mpox) infections among various groups based on ethnicity, sexual partners, and gender. The study includes data from 2,646 to 4,002 patients across various outcomes. Among racial demographics, black populations show a lower odds ratio for mpox compared to white populations (OR=0.08 [0.01, 0.45], 95% CI, p=0.004). However, no statistically significant difference is found when comparing black populations with Hispanic or Asian populations (OR=0.72 [0.46, 1.11], p=0.13). There was a substantial disparity between gay, bisexual and other men-who-have-sex-with-men (GBMSM) and heterosexual populations, with significantly higher odds of mpox among the former (OR=393.80, 95% CI: [82.45, 180.85], p<0.00001). Analysis of sexual partners indicates a significant difference in infection risk between individuals with zero to one sexual partner and those with more than two partners (OR=0.06 [0.01, 0.28], p=0.0005). Additionally, there is a substantial difference in infection risk between male and female populations (OR=3868.02, p<0.00001). These findings emphasize the importance of considering demographic factors in understanding mpox transmission and risk profiles. Targeted research and intervention strategies are required to address the identified disparities and mitigate the spread of mpox.
MeSH term(s)	Humans ; Female ; Male ; Mpox (monkeypox) ; Homosexuality, Male ; Sexual and Gender Minorities ; Demography
Language	English
Publishing date	2024-01-22
Publishing country	Italy
Document type	Meta-Analysis ; Journal Article
ZDB-ID	756168-4
ISSN	1121-7138 ; 0391-5352
ISSN	1121-7138 ; 0391-5352
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2267: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Risk factors and mortality outcomes of COVID-19 in people living with HIV: a systematic review and meta-analysis.

Kandeel, Mahmoud

AIDS reviews

2024 Volume 26, Issue 1, Page(s) 1–14

Abstract: This study was performed to reveal the risk factors associated with mortality in people living with HIV (PLHIV) who were diagnosed with COVID-19. Studies reporting deaths among PLHIV and infected with SARS-CoV-2 were investigated. After protocol setup ... ...

Abstract	This study was performed to reveal the risk factors associated with mortality in people living with HIV (PLHIV) who were diagnosed with COVID-19. Studies reporting deaths among PLHIV and infected with SARS-CoV-2 were investigated. After protocol setup and registration, the extracted sources were categorized and assessed for quality. This study examined ten articles with a total of 46,136 patients. Patients aged ≥ 60 years (hazard ratio [HR] = 2.22; 95% CI: 1.617, 3.050; p < 0.001), male (HR = 1.668; 95% CI: 1.179, 2.361; p = 0.004), and people with diabetes (risk ratio [RR] = 3.34; 95% CI: 1.45, 7.68; p = 0.005) were at higher risk of death. Adherence to antiretroviral therapy (ART) reduced mortality risk (RR = 0.90; 95% CI: 0.83, 0.98; p = 0.02). Patients in the survival groups showed a statistically significant lower mean of C-reactive protein (mean difference = 114.08; 95% -74.05, 154.10; p < 0.001). Deceased patients showed higher mean levels of interleukin-6 (IL-6). Chronic respiratory disorders, hypertension, oxygen requirement, admission to an intensive care unit, D-dimer levels, and HIV viral load < 50 copies RNA/mL before admission did not show statistically significant differences between the deceased and survival groups. ART therapy reduced mortality risk (RR = 0.90; 95% 0.83, 0.98; p = 0.02). Identifying PLHIV at higher mortality risk could improve the outcomes of COVID-19 by stratifying these patients to the most effective treatment in a timely fashion.
MeSH term(s)	Humans ; Male ; COVID-19/complications ; HIV Infections/complications ; SARS-CoV-2 ; Risk Factors ; Treatment Outcome
Language	English
Publishing date	2024-03-26
Publishing country	Spain
Document type	Meta-Analysis ; Systematic Review ; Journal Article
ZDB-ID	2086783-9
ISSN	1698-6997 ; 1139-6121
ISSN (online)	1698-6997
ISSN	1139-6121
DOI	10.24875/AIDSRev.23000017
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5711: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Oncogenic Viruses-Encoded microRNAs and Their Role in the Progression of Cancer: Emerging Targets for Antiviral and Anticancer Therapies.

Kandeel, Mahmoud

Pharmaceuticals (Basel, Switzerland)

2023 Volume 16, Issue 4

Abstract: Approximately 20% of all cases of human cancer are caused by viral infections. Although a great number of viruses are capable of causing a wide range of tumors in animals, only seven of these viruses have been linked to human malignancies and are ... ...

Abstract	Approximately 20% of all cases of human cancer are caused by viral infections. Although a great number of viruses are capable of causing a wide range of tumors in animals, only seven of these viruses have been linked to human malignancies and are presently classified as oncogenic viruses. These include the Epstein-Barr virus (EBV), human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), Merkel cell polyomavirus (MCPyV), human herpesvirus 8 (HHV8), and human T-cell lymphotropic virus type 1 (HTLV-1). Some other viruses, such as the human immunodeficiency virus (HIV), are associated with highly oncogenic activities. It is possible that virally encoded microRNAs (miRNAs), which are ideal non-immunogenic tools for viruses, play a significant role in carcinogenic processes. Both virus-derived microRNAs (v-miRNAs) and host-derived microRNAs (host miRNAs) can influence the expression of various host-derived and virus-derived genes. The current literature review begins with an explanation of how viral infections might exert their oncogenic properties in human neoplasms, and then goes on to discuss the impact of diverse viral infections on the advancement of several types of malignancies via the expression of v-miRNAs. Finally, the role of new anti-oncoviral therapies that could target these neoplasms is discussed.
Language	English
Publishing date	2023-03-23
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2193542-7
ISSN	1424-8247
ISSN	1424-8247
DOI	10.3390/ph16040485
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: An overview of the recent progress in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) drug discovery.

Kandeel, Mahmoud

Expert opinion on drug discovery

2023 Volume 18, Issue 4, Page(s) 385–400

Abstract: Introduction: The Middle East respiratory syndrome coronavirus (MERS-CoV) has remained a public health concern since it first emerged in 2012. Although many potential treatments for MERS-CoV have been developed and tested, none have had complete success ...

Abstract	Introduction: The Middle East respiratory syndrome coronavirus (MERS-CoV) has remained a public health concern since it first emerged in 2012. Although many potential treatments for MERS-CoV have been developed and tested, none have had complete success in stopping the spread of this deadly disease. MERS-CoV replication comprises attachment, entry, fusion and replication steps. Targeting these events may lead to the creation of medications that effectively treat MERS-CoV infection. Areas covered: This review updates the research on the development of inhibitors of MERS-CoV. The main topics are MERS-CoV‒related proteins and host cell proteins that are involved in viral protein activation and infection. Expert opinion: Research on discovering drugs that can inhibit MERS-CoV started at a slow pace, and although efforts have steadily increased, clinical trials for new drugs specifically targeting MERS-CoV have not been extensive enough. The explosion in efforts to find new medications for the SARS-CoV-2 virus indirectly enhanced the volume of data on MERS-CoV inhibition by including MERS-CoV in drug assays. The appearance of COVID-19 completely transformed the data available on MERS-CoV inhibition. Despite the fact that new infected cases are constantly being diagnosed, there are currently no approved vaccines for or inhibitors of MERS-CoV.
MeSH term(s)	Humans ; Middle East Respiratory Syndrome Coronavirus ; COVID-19 ; SARS-CoV-2 ; Antiviral Agents/pharmacology ; Drug Discovery
Chemical Substances	Antiviral Agents
Language	English
Publishing date	2023-03-27
Publishing country	England
Document type	Review ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2259618-5
ISSN	1746-045X ; 1746-0441
ISSN (online)	1746-045X
ISSN	1746-0441
DOI	10.1080/17460441.2023.2192921
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6388: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The impact of the M184V resistance mutation on treatment outcomes in patients with HIV infection: a systematic review and meta-analysis.

Kandeel, Mahmoud

AIDS reviews

2023 Volume 26, Issue 3, Page(s) 136–144

Abstract: HIV is a global deliberating infectious disease. Of note, more than 36 million people living with HIV (PLHIV) with approximately newly diagnosed 1.5 million cases annually. M184V is a single base mutation in the highly conserved YMDD domain of reverse ... ...

Abstract	HIV is a global deliberating infectious disease. Of note, more than 36 million people living with HIV (PLHIV) with approximately newly diagnosed 1.5 million cases annually. M184V is a single base mutation in the highly conserved YMDD domain of reverse transcriptase (RT). It is one of the most encountered resistances associated with mutations to nucleoside RT inhibitors. There were continuous efforts to evaluate the impact of M184V mutation on the treatment outcomes in PLHIV. Therefore, the present systematic review was executed to reveal the virological failure, virological suppression, and resistance to antiretroviral therapy (ART) regimens in PLHIV with the M184V mutation. All clinical studies comparing the treatment outcomes among PLHIV harboring or not harboring M184V mutation were appropriate for systematic review and meta-analysis. The present systematic review included six articles, encompassing 4760 PLHIV. Of them, 1222 (25.67%) patients had M184V mutation, while 3538 (74.32%) PLHIV did not. The meta-analysis showed that patients with M184V mutation were 1.87 times more liable to virological failure (risk ratio [RR] 1.87; 95% 1.09, 3.20; p = 0.02). Furthermore, pooling the data from two studies revealed a significantly higher risk of viral blips (RR 2.26; 95% 1.47, 3.46; p = 0.0002). Concerning discontinuation of ART, there was no statistical difference between patients with and without M184V mutation (RR: 0.99; 95% 0.78, 1.25; p = 0.90). The present study revealed the negative impact of the M184V mutation on treatment outcomes in PLHIV. This included a higher risk of virological failure and viral blips, relative to patients without the mutation. Such patients may benefit from more aggressive and combined therapy for better disease management.
MeSH term(s)	Humans ; Anti-HIV Agents/therapeutic use ; Anti-HIV Agents/pharmacology ; Drug Resistance, Viral/genetics ; HIV Infections/drug therapy ; HIV Reverse Transcriptase/genetics ; HIV-1/genetics ; Mutation ; Reverse Transcriptase Inhibitors/therapeutic use ; Treatment Outcome
Chemical Substances	Anti-HIV Agents ; HIV Reverse Transcriptase (EC 2.7.7.49) ; Reverse Transcriptase Inhibitors
Language	English
Publishing date	2023-10-24
Publishing country	Spain
Document type	Meta-Analysis ; Systematic Review ; Journal Article
ZDB-ID	2086783-9
ISSN	1698-6997 ; 1139-6121
ISSN (online)	1698-6997
ISSN	1139-6121
DOI	10.24875/AIDSRev.23000002
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5711: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis.

Kandeel, Mahmoud

Frontiers in pharmacology

2022 Volume 13, Page(s) 926717

Abstract: Diabetes mellitus (DM) is one of the leading causes of morbidity and mortality worldwide. DM patients with diabetic neuropathy (DN) usually present with distal pain, sensorimotor polyneuropathy, postural hypotension, or erectile dysfunction. They also ... ...

Abstract	Diabetes mellitus (DM) is one of the leading causes of morbidity and mortality worldwide. DM patients with diabetic neuropathy (DN) usually present with distal pain, sensorimotor polyneuropathy, postural hypotension, or erectile dysfunction. They also may present with other nerve pathologies such as inflammatory neuropathies and carpal tunnel syndrome. We conducted a systematic review and meta-analysis to assess the benefits of using sodium-glucose co-transporter-2 inhibitors (SGLT2Is) to manage DN. An extensive systematic literature review was conducted to include all articles published up to 24 February 2022. All clinical studies included patients with DM and reported the outcomes of SGLT2I on diabetes-associated neuropathy. Six studies were identified for meta-analysis, including a total of 5312 diabetic patients. The average age of the included patients ranged from 41 to 74 years and 34-73 years in the SGLT2I treatment and control groups, respectively. SGLT2I moderately improved the manifestations of diabetic peripheral neuropathy events and nerve conduction velocity. Furthermore, the SGLT2I treatment group had a statistically significant higher mean heart-to-mediastinum ratio (MD 0.41; 95% 0.17, 0.64;
Language	English
Publishing date	2022-07-11
Publishing country	Switzerland
Document type	Systematic Review
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2022.926717
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Meta-analysis of seroprevalence and zoonotic infections of Middle East respiratory syndrome coronavirus (MERS-CoV): A one-health perspective.

Kandeel, Mahmoud

One health (Amsterdam, Netherlands)

2022 Volume 15, Page(s) 100436

Abstract: The zoonotic Middle East respiratory syndrome (MERS) is caused by an emerging beta-coronavirus (CoV). The majority of MERS studies have included scattered data from sub-Saharan Africa and the Middle East, and these data have not been analyzed ... ...

Abstract	The zoonotic Middle East respiratory syndrome (MERS) is caused by an emerging beta-coronavirus (CoV). The majority of MERS studies have included scattered data from sub-Saharan Africa and the Middle East, and these data have not been analyzed collectively. In this work, a meta-analysis of these studies was conducted to coalesce these results, determine the prevalence and seroprevalence of MERS-CoV in camels and humans, and examine how zoonotic infection rates in dromedary camels are related to human infection rates. After extracting the collected data, the prevalence and seroprevalence at a 95% confidence interval (CI) using a fixed-effects inverse-variance meta-analysis was conducted. Thirteen studies were included. Eight studies included 2905 samples from dromedary camels, of which 1108 (38.14%) were positive for the virus. The prevalence was 8.75[-13.47, 30.98] at 95% CI in dromedary camels and 0.03[-35.23, 35.28] at 95% CI in humans. Ten studies included 7176 serum samples, 5788 (80.66%) of which were positive. The seroprevalence was 20.69[-4.60, 45.99] at 95% CI. The prevalence of MERS-CoV was moderate to high, but the seroprevalence was high. Despite the high prevalence of the virus in camel herds, zoonotic transmissions were not widespread. Further longitudinal and cross-sectional follow-up studies are recommended to provide solid control of MERS-CoV transmission.
Language	English
Publishing date	2022-09-23
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2834831-X
ISSN	2352-7714
ISSN	2352-7714
DOI	10.1016/j.onehlt.2022.100436
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Meta-analysis of seroprevalence and zoonotic infections of Middle East respiratory syndrome coronavirus (MERS-CoV)

Mahmoud Kandeel

One Health, Vol 15, Iss , Pp 100436- (2022)

A one-health perspective

2022

Abstract	The zoonotic Middle East respiratory syndrome (MERS) is caused by an emerging beta-coronavirus (CoV). The majority of MERS studies have included scattered data from sub-Saharan Africa and the Middle East, and these data have not been analyzed collectively. In this work, a meta-analysis of these studies was conducted to coalesce these results, determine the prevalence and seroprevalence of MERS-CoV in camels and humans, and examine how zoonotic infection rates in dromedary camels are related to human infection rates. After extracting the collected data, the prevalence and seroprevalence at a 95% confidence interval (CI) using a fixed-effects inverse-variance meta-analysis was conducted. Thirteen studies were included. Eight studies included 2905 samples from dromedary camels, of which 1108 (38.14%) were positive for the virus. The prevalence was 8.75[−13.47, 30.98] at 95% CI in dromedary camels and 0.03[−35.23, 35.28] at 95% CI in humans. Ten studies included 7176 serum samples, 5788 (80.66%) of which were positive. The seroprevalence was 20.69[−4.60, 45.99] at 95% CI. The prevalence of MERS-CoV was moderate to high, but the seroprevalence was high. Despite the high prevalence of the virus in camel herds, zoonotic transmissions were not widespread. Further longitudinal and cross-sectional follow-up studies are recommended to provide solid control of MERS-CoV transmission.
Keywords	MERS-CoV ; Prevalence ; Camel ; Meta-analysis ; Zoonosis ; Medicine (General) ; R5-920
Subject code	306
Language	English
Publishing date	2022-12-01T00:00:00Z
Publisher	Elsevier
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Meta-analysis of seroprevalence and zoonotic infections of Middle East respiratory syndrome coronavirus (MERS-CoV): A one-health perspective

Kandeel, Mahmoud

One health. 2022 Sept. 21,

2022

Abstract	The zoonotic Middle East respiratory syndrome (MERS) is caused by an emerging beta-coronavirus (CoV). The majority of MERS studies have included scattered data from sub-Saharan Africa and the Middle East, and these data have not been analyzed collectively. In this work, a meta-analysis of these studies was conducted to coalesce these results, determine the prevalence and seroprevalence of MERS-CoV in camels and humans, and examine how zoonotic infection rates in dromedary camels are related to human infection rates. After extracting the collected data, the prevalence and seroprevalence at a 95% confidence interval (CI) using a fixed-effects inverse-variance meta-analysis was conducted. Thirteen studies were included. Eight studies included 2905 samples from dromedary camels, of which 1108 (38.14%) were positive for the virus. The prevalence was 8.75[−13.47, 30.98] at 95% CI in dromedary camels and 0.03[−35.23, 35.28] at 95% CI in humans. Ten studies included 7176 serum samples, 5788 (80.66%) of which were positive. The seroprevalence was 20.69[−4.60, 45.99] at 95% CI. The prevalence of MERS-CoV was moderate to high, but the seroprevalence was high. Despite the high prevalence of the virus in camel herds, zoonotic transmissions were not widespread. Further longitudinal and cross-sectional follow-up studies are recommended to provide solid control of MERS-CoV transmission.
Keywords	Camelus dromedarius ; Coronavirus infections ; Middle East respiratory syndrome coronavirus ; blood serum ; camels ; confidence interval ; meta-analysis ; seroprevalence ; viruses ; zoonoses ; Middle East ; Sub-Saharan Africa
Language	English
Dates of publication	2022-0921
Publishing place	Elsevier B.V.
Document type	Article
Note	Pre-press version
ZDB-ID	2834831-X
ISSN	2352-7714
ISSN	2352-7714
DOI	10.1016/j.onehlt.2022.100436
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article ; Online: Hegemony of inflammation in atherosclerosis and coronary artery disease.

Attiq, Ali / Afzal, Sheryar / Ahmad, Waqas / Kandeel, Mahmoud

European journal of pharmacology

2024 Volume 966, Page(s) 176338

Abstract: Inflammation drives coronary artery disease and atherosclerosis implications. Lipoprotein entry, retention, and oxidative modification cause endothelial damage, triggering innate and adaptive immune responses. Recruited immune cells orchestrate the early ...

Abstract	Inflammation drives coronary artery disease and atherosclerosis implications. Lipoprotein entry, retention, and oxidative modification cause endothelial damage, triggering innate and adaptive immune responses. Recruited immune cells orchestrate the early atherosclerotic lesions by releasing proinflammatory cytokines, expediting the foam cell formation, intraplaque haemorrhage, secretion of matrix-degrading enzymes, and lesion progression, eventually promoting coronary artery syndrome via various inflammatory cascades. In addition, soluble mediators disrupt the dynamic anti- and prothrombotic balance maintained by endothelial cells and pave the way for coronary artery disease such as angina pectoris. Recent studies have established a relationship between elevated levels of inflammatory markers, including C-reactive protein (CRP), interleukins (IL-6, IL-1β), and tumour necrosis factor-alpha (TNF-α) with the severity of CAD and the possibility of future cardiovascular events. High-sensitivity C-reactive protein (hs-CRP) is a marker for assessing systemic inflammation and predicting the risk of developing CAD based on its peak plasma levels. Hence, understanding cross-talk interactions of inflammation, atherogenesis, and CAD is highly warranted to recalculate the risk factors that activate and propagate arterial lesions and devise therapeutic strategies accordingly. Cholesterol-inflammation lowering agents (statins), monoclonal antibodies targeting IL-1 and IL-6 (canakinumab and tocilizumab), disease-modifying antirheumatic drugs (methotrexate), sodium-glucose transport protein-2 (SGLT2) inhibitors, colchicine and xanthene oxidase inhibitor (allopurinol) have shown promising results in reducing inflammation, regressing atherogenic plaque and modifying the course of CAD. Here, we review the complex interplay between inflammatory, endothelial, smooth muscle and foam cells. Moreover, the putative role of inflammation in atherosclerotic CAD, underlying mechanisms and potential therapeutic implications are also discussed herein.
MeSH term(s)	Humans ; Coronary Artery Disease/complications ; Coronary Artery Disease/drug therapy ; C-Reactive Protein ; Interleukin-6 ; Endothelial Cells/metabolism ; Atherosclerosis/metabolism ; Inflammation/complications ; Inflammation/drug therapy
Chemical Substances	C-Reactive Protein (9007-41-4) ; Interleukin-6
Language	English
Publishing date	2024-01-17
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	80121-5
ISSN	1879-0712 ; 0014-2999
ISSN (online)	1879-0712
ISSN	0014-2999
DOI	10.1016/j.ejphar.2024.176338
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 522: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito